Thông tin thuốc gốc
Chỉ định và Liều dùng
Parkinson's disease
Adult: For intermittent treatment of episodic motor fluctuations (OFF episodes) in patients treated with levodopa/dopa-decarboxylase inhibitor (e.g. carbidopa): 84 mg via oral inhalation, up to 5 times daily as needed when symptoms of an OFF period return. Max: 84 mg/dose; 420 mg/day.
Cách dùng
Should be taken with food. May be taken w/ meals to reduce GI discomfort. Keep a consistent diet.
Chống chỉ định
Concomitant use or within 14 days of MAOIs use.
Thận trọng
Patient with history of psychotic disorder; major psychotic disorder, glaucoma, severe CV disease, respiratory disease. Avoid abrupt withdrawal or rapid dose reduction. Elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Abnormal thinking and behavioural changes (e.g. agitation, aggressive behaviour, confusion, paranoid ideation, delirium, delusions, disorientation, and psychotic-like behaviour), impulse control or compulsive disorders (e.g. increased sexual urges, intense urges to spend money, pathological gambling, binge or compulsive eating), hallucinations that may be accompanied by confusion, insomnia and excessive dreaming; somnolence and falling asleep while engaged in activities of daily living; dyskinesia; withdrawal-emergent hyperpyrexia and confusion; bronchospasm, increased intraocular pressure.
Cardiac disorders: Chest discomfort.
Gastrointestinal disorders: Nausea, vomiting.
Injury, poisoning and procedural complications: Fall, laceration, skin abrasion.
Investigations: Increased bilirubin, decreased red blood cell count, positive direct Coomb's test.
Musculoskeletal and connective tissue disorders: Limb pain.
Nervous system disorders: Headache.
Psychiatric disorders: Insomnia.
Respiratory, thoracic and mediastinal disorders: Cough, upper respiratory tract infection, nasopharyngitis, pneumonia, bronchitis, sputum and nasal discharge discolouration, oropharyngeal pain, choking sensation.
Vascular disorders: Orthostatic hypotension.
Gastroenteral/PO: C (FDA pregnancy category C if used in combination therapy w/ carbidopa.)
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, somnolence or reduced alertness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor LFT, BUN, CBC, direct antiglobulin, and intraocular pressure (in patients with glaucoma) as clinically indicated. Monitor for signs of CNS related side effects.
Quá liều
Symptoms: CNS disturbance, more severe psychiatric problems, risk of CV disturbance (e.g. tachycardia, hypotension), rhabdomyolysis and transient renal insufficiency. Management: Supportive treatment. For the development of arrhythmias, monitor ECG and antiarrhythmic therapy may be given as needed.
Tương tác
May enhance the orthostatic hypotensive effect of MAOI Type B (e.g. rasagiline, selegiline, safinamide). Diminished therapeutic effect with isoniazid and dopamine D2 receptor antagonists (e.g. metoclopramide, phenothiazines, butyrophenones, risperidone). Reduced bioavailability with iron salts or multivitamins/minerals (with A, D, E, K, folate). May enhance the hypotensive effect of antihypertensives.
Potentially Fatal: May enhance the adverse effect of MAOIs (e.g. phenelzine, tranylcypromine) particularly on the development of hypertensive reactions.
Ảnh hưởng đến kết quả xét nghiệm
False diagnosis for pheochromocytoma based on plasma and urine levels of catecholamines. False-positive reaction for urinary ketone bodies when a test tape is used for determination of ketonuria. False-negative tests may result with use of glucose-oxidase methods of testing for glucosuria.
Tác dụng
Description: Levodopa, a precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine by striatal enzymes, thereby relieving the symptoms of Parkinson's disease.
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: Approx 70% (relative to availability from immediate-release formulation). Time to peak plasma concentration: Median: 0.5 hour (0.17-2 hours).
Distribution: Crosses the placenta and blood-brain barrier; enters breast milk. Apparent volume of distribution: 168 L. Plasma protein binding: Approx 10-30%.
Metabolism: Extensively metabolised via decarboxylation by L-aromatic amino acid decarboxylase to dihydrophenylacetic acid (DOPAC) and homovanillic acid (HVA) and O-methylation by catechol-O methyltransferase (COMT).
Excretion: Mainly via urine (80% as dihydroxyphenylacetic acid and homovanillic acid); faeces (as unchanged drug). Elimination half-life: 2.3 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Levodopa, CID=6047, https://pubchem.ncbi.nlm.nih.gov/compound/Levodopa (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C. Protect from moisture. Store cap in original package and only remove immediately before use.
Phân loại MIMS
Thuốc trị bệnh Parkinson
Phân loại ATC
N04BA01 - levodopa ; Belongs to the class of dopa and dopa derivative dopaminergic agents. Used in the management of Parkinson's disease.
Tài liệu tham khảo
Buckingham R (ed). Levodopa. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/08/2021.

Inbrija (Acorda Therapeutics, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/08/2021.

Inbrija 33 mg Inhalation Powder, Hard Capsules (Acorda Therapeutics Ireland Limited). European Medicines Agency [online]. Accessed 04/08/2021.

Levodopa (Oral Inhalation). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/08/2021.

Levodopa. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 04/08/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Levodopa từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in